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Abstract
Virus infection of a cell generally evokes an immune response by the host to defeat the intruder in its effort. Many viruses
have developed an array of strategies to evade or antagonize host antiviral responses. Kaposi’s sarcoma-associated
herpesvirus (KSHV) is demonstrated in this report to be able to prevent activation of host antiviral defense mechanisms
upon infection. Cells infected with wild-type KSHV were permissive for superinfection with vesicular stomatitis virus (VSV),
suggesting that KSHV virions fail to induce host antiviral responses. We previously showed that ORF45, a KSHV immediate-
early protein as well as a tegument protein of virions, interacts with IRF-7 and inhibits virus-mediated type I interferon
induction by blocking IRF-7 phosphorylation and nuclear translocation (Zhu et al., Proc. Natl. Acad. Sci. USA. 99:5573-5578,
2002). Here, using an ORF45-null recombinant virus, we demonstrate a profound role of ORF45 in inhibiting host antiviral
responses. Infection of cells with an ORF45-null mutant recombinant KSHV (BAC-stop45) triggered an immune response
that resisted VSV super-infection, concomitantly associated with appreciable increases in transcription of type I IFN and
downstream anti-viral effector genes. Gain-of-function analysis showed that ectopic expression of ORF45 in human
fibroblast cells by a lentivirus vector decreased the antiviral responses of the cells. shRNA-mediated silencing of IRF-7, that
predominantly regulates both the early and late phase induction of type I IFNs, clearly indicated its critical contribution to
the innate antiviral responses generated against incoming KSHV particles. Thus ORF45 through its targeting of the crucial
IRF-7 regulated type I IFN antiviral responses significantly contributes to the KSHV survival immediately following a primary
infection allowing for progression onto subsequent stages in its life-cycle.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus 8 (HHV-8), is a human DNA tumor virus
belonging to the gamma herpesviridae family [1,2]. It represents
one of the latest additions to the DNA tumor virus group and is
etiologically associated with Kaposi’s sarcoma (KS), a malignant
neoplasm of endothelial origin [1]. KSHV is also unequivocally
associated with certain lymphoproliferative disorders, namely
primary effusion lymphoma (PEL) and multicentric Castleman’s
disease (MCD) [3,4].
The infectious cycle of herpesviruses starts with the virus
binding to the cell surface followed by the release of the viral
components into the cell. The host cell responds to these events
through the creation of an antiviral state, predominantly
associated with the synthesis and secretion of soluble type I
interferon (IFN-a/b), that make up vital components of the host
innate immune system [5,6]. This is exemplified in related
herpesviruses, like herpes simplex virus (HSV) and human
cytomegalovirus (HCMV), wherein the binding of the respective
envelope glycoproteins, gD and gB, to the cell surface receptors,
trigger the host cell antiviral responses through type I IFN
signaling [7,8]. In KSHV also, the initial interaction of the viral
glycoprotein gpK8.1 with cell surface components was shown to
trigger the type I IFN pathway [9].
In spite of the above observation, following primary infection of
cultured cells with KSHV, there was no significant induction of
type I IFNs or their receptors [10]. Further the antiviral response
elicited by gpK8.1 was clearly inhibited by infection of cells with
UV-treated KSHV virions [9]. These findings clearly indicated
that a possible virion component efficiently disarms the host
immune response immediately following viral infection. Such a
phenomenon is also seen with related herpesviruses like HCMV
and rhesus CMV (RhCMV) where the tegument components
likely play pivotal roles in inhibition of the host immune responses
[11–13]. In HSV-1 also a similar antagonism of the host innate
immune responses is seen which however occurs only following
viral gene expression [14]. Avoidance of the initial host antiviral
state thus allows to virus to successfully establish an infection
allowing its further progression down the viral life-cycle.
The type I IFNs modulating the innate antiviral response trigger
the transcription of the IFN-stimulated genes (ISGs) which
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significantly reducing the virus burden [15,16]. Type I IFN
transcription is primarily controlled by two IFN regulatory factors
(IRFs), IRF-3 and IRF-7 [17–19]. The constitutively expressed
IRF-3, upon initial viral infection, undergoes activation and
induces expression of IFN-b (early phase). This initial induction of
IFN-b stimulates the type I IFN receptor resulting in the activation
of IRF-7, which efficiently induces both the IFN-a and the IFN -b
genes initiating a positive feedback loop (late phase) [17–19].
Though this classical pathway reveals an important role of IRF-7
only in the later stages of type I IFN induction, recent studies using
IRF-7 deficient (IRF-7
2/2) mice have provided for a significantly
different picture [20,21]. Accordingly the endogenously expressed,
low level IRF-7 (in uninfected cells) gets activated following a
primary viral invasion and brings about the initial induction of
type I IFN. This subsequently further activates IRF-7 initiating a
positive feedback loop aimed at robust late stage induction of
IFNs. Thus by participating in both the initial and the late phases
of type I IFN secretion, IRF-7 emerged as the predominant factor
controlling type I IFN mediated innate immune responses [20,21].
A new and exciting pathway for the robust induction of type I IFNs
also involves activation of the toll like receptor (TLR) molecules
following viral invasion [20,21]. This is typified by the activation of
TLR9 sub-family of proteins that subsequently recruits an adaptor
protein, the myeloid differentiation primary response gene 88
(MyD88). This adaptor protein through exclusive interaction with
and activation of IRF-7, results in type I IFN secretion, governing the
induction of CD8
+ T-cell responses contributing to adaptive
immunity in dendritic cells (DCs) [20,21]. This observation gains
morevalue in the light of certainstudies suggestingthat DCscouldbe
infected with KSHV and could possibly play vital roles in the
transmission and pathogenesis of KSHV [22,23].
From the preceding observations it becomes quite evident that
IRF-7 is the master regulator of the host immune responses,
controlling both innate and adaptive immunity. Thus given the
significance of IRF-7 in the induction of immune responses and
the fact that a virion component of KSHV does disarm the host
immune response, our attention turned to the study of the
candidate virion component proteins that participate in the
selective inhibition of IRF-7 transcription. We had earlier shown
that ORF45, an immediate-early protein [24] and a virion
component (tegument) protein of KSHV [25,26], interacts with
IRF-7 and suppresses its activation, thereby efficiently inhibiting
the virus-mediated type I IFN induction [27]. Thus, ORF45 might
be critical in defeating the host antiviral responses following
primary KSHV infection. Tegument proteins even in closely
related herpesviruses like HCMV [11,12] and Epstein-Barr virus
(EBV) [28] provide for a similar role. In this report we thus
investigated the possible role of ORF45 in overcoming the innate
host immune responses. We first show that KSHV does not induce
an antiviral state following primary infection and also subsequently
reveal the likely virion component responsible for this to be the
tegument protein ORF45. We also show that IRF-7 critically
contributes to the primary immune response elicited against
incoming KSHV particles. Thus this study convincingly illustrates
the biological significance of the ORF45-IRF-7 interaction
following primary infection of cells with KSHV viral particles.
Results
KSHV does not induce an antiviral state during de novo
infection
Viral infection and ongoing lytic replication are generally under
host antiviral surveillance. These viral events induce specific
antiviral immune responses by the host cell constituted by the
synthesis of type I IFNs (IFN-a/b) that activates the transcription
of a group of downstream ISGs that encode antiviral IFN effector
proteins [15]. To assure successful infection and lytic replication,
many viruses including related herpesviruses like HSV-1, HCMV,
RhCMV and EBV have developed strategies to specifically evade
these elicited host immune responses [11–14,28]. Thus, we wanted
to investigate if KSHV is also able to avoid such host antiviral
responses following primary infection. To address this question, we
adapted a plaque reduction assay in our study. A similar assay also
has been used to demonstrate that herpes simplex virus type I
(HSV-1) is able to disarm IFN antiviral responses [14]. KSHV
virions collected five days following 12-O-tetradecanoylphorbol-
13-acetate (TPA) induction of BCBL-1 cells (harboring KSHV in
the latent phase), were concentrated and gradient purified. A
portion of these virions were subjected to UV-irradiation. Human
foreskin fibroblast (HFF) cells were infected with 5 genome copies
per cell of intact or UV-inactivated KSHV and at 16 hours
postinfection were superinfected with approximately 100 plaque
forming units (Pfu) of vesicular stomatitis virus (VSV). VSV is a
negative strand RNA virus, the growth of which is sensitive to the
effects of the IFN pathways, hence has been commonly employed
as a useful indicator to assess the antiviral status of a cell following
herpesviral infection [8,14]. VSV replication is indicated by
formation of characteristic plaques which upon crystal violet
staining allows for convenient visualization.
HFF cells that were infected with either UV-irradiated HSV-1
(MOI of 5) or IFNa (1000 units/ml) resisted VSV superinfection
as shown by the near absence of VSV specific plaques (Fig. 1A).
This was in agreement with earlier findings wherein HSV primary
infection elicits immune responses which are disarmed only
following immediate-early gene expression [14]. Interestingly in
KSHV-infected cells, no apparent reduction of VSV plaques was
observed regardless of UV treatment of KSHV (Fig. 1A). Even
when HFF cells were infected with a higher MOI of KSHV (50
genomes per cell), similar results were obtained (data not shown).
Merged/overlayed confocal immunoflorescence images revealed
the presence of both KSHV latent nuclear antigen, LANA (green
nuclear staining) and VSV glycoprotein G, VSV G (red
cytoplasmic staining) in the same cell (Fig. 1B). These results were
in corroboration to an earlier study [9] thereby suggesting that
primary infection with KSHV dose not lead to an antiviral state
and permits subsequent superinfection of KSHV-infected cells
with VSV.
The ablation of an effective antiviral response might rest in lack
of molecular signals to trigger host cellular responses. However,
modulation of several host cellular signaling pathways following
primary infection with KSHV [10] combined with the fact that
type I IFN mediated antiviral immune responses are known to be
generated following infection with other related herpesviruses
[7,8,11–14,28] argues against this notion. Thus an alternative
possibility of KSHV triggering an initial antiviral response which is
quickly and efficiently disarmed seems much more feasible. Hence
we next went on to investigate if an effective type I IFN based
immune response is generated in the first place subsequent to
KSHV primary infection. In related herpesviruses like HSV-1 and
HCMV, binding of the envelope glycoproteins to the host cell
surface, induces the type I IFN signaling [7,8]. To investigate
occurrence of a similar such phenomenon in KSHV too, we used a
sensitive luciferase-reporter system to determine whether KSHV
major glycoproteins K8.1 or gB activates the type I IFN pathway.
Human embryonic kidney (HEK) 293T cells co-transfected with
an IFNA1 promoter reporter construct (pGL-IFNA1) and an IRF-
7 expression vector (pCR3.1-IRF-7) were infected 24 h later at
Immune Evasion by KSHV ORF45
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10573increasing inputs of either purified envelope glycoproteins (K8.1 or
gB) or gradient purified intact or UV-inactivated KSHV. As
expected, challenge of cells with the UV-irradiated HSV-1
(control) at increasing MOIs of 1 and 5 proportionately increased
the IFNA1 promoter transcription 4-fold and 8-fold respectively
(Fig. 2). Interestingly increasing inputs of the KSHV K8.1 protein,
corresponding to 1 and 5 mg/ml, concomitantly increased the
IFNA1 promoter activity 3 and 7-fold respectively, though purified
gB had no such effect at both concentrations (Fig. 2). Both intact
and UV-treated KSHV virions did not reveal any noticeable
Figure 1. Evaluation of antiviral state subsequent to KSHV primary infection. (A) Human foreskin fibroblast (HFF) monolayers were mock-
infected or infected with intact/UV-inactivated KSHV virions (5 viral genomes/cell) or UV-inactivated HSV-1 (multiplicity of infection [MOI] of 5)o r
treated with IFNa (1000 units/ml). After 16 h, 100 plaque forming units (Pfu) of vesicular stomatitis virus (VSV) was added to each well and then
overlayed with 1% methylcellulose in DMEM. Cells were fixed and stained with crystal violet 24 h later for convenient visualization of VSV induced
plaques. (B) Confocal immunoflorescence revealing dual infection of HFF cells with KSHV and VSV. HFF cells grown on coverslips were infected first
with intact KSHV virions and subsequently superinfected with VSV. Cells were fixed, permeabilized and subjected to a double labeled
immunoflorescence (IFA) with mouse monoclonal antibody against KSHV LANA (nuclear green florescence) and rabbit polyclonal antibody against
VSV glycoprotein (cytoplasmic red florescennce). The right panel shows the merged image.
doi:10.1371/journal.pone.0010573.g001
Figure 2. Induction of IFN signaling by KSHV soluble KSHV K8.1 glycoprotein but not by KSHV virions. Subconfluent 293T cells grown
in 24-well plates were transfected with pGL-IFNA1 (a luciferase report vector driven by the IFNA1 promoter), an IRF-7 expressing plasmid (pCR3.1-IRF-
7) cloned into a pCR3.1 vector and a pRL-TK reporter (Renilla luciferase as an internal control) plasmid. At 24 h post-transfection, cells were infected
with the indicated viruses at the indicated MOI or treated with purified soluble KSHV K8.1 or gB glycoproteins at increasing concentrations of 1 and
5 mg/ml, respectively. Six hours following infection, cell lysates were prepared and activation of the IFNA1 promoter transcription was evaluated
using a dual luciferase assay kit.
doi:10.1371/journal.pone.0010573.g002
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infected cells (Fig. 2). These results demonstrated that the KSHV
envelope glycoprotein K8.1 triggers host antiviral signaling which
is quickly ablated by some virion component(s).
KSHV tegument protein ORF45 is delivered into cells
during de novo infection
Given that a virion component likely disarms the initial host
elicited immune response, we hypothesized that a highly probable
virion protein to mimic this could be ORF45. This was based on
two earlier observations: (i) ORF45 is a major component of the
KSHV viral tegument [25,26]; (ii) ORF45 characteristically
inhibits the activation of IRF-7 [27], the master regulator essential
for both the initial and the late phase induction of type I IFNs
[20,21]. As shown in Fig. 3A, ORF45 was readily detected by
immunoflorescence as early as 1 h following infection of HFF cells.
Similar findings were also reproducible following infection of both
293T and Vero cells (data not shown). Western blot analysis using
infected cell lysates also revealed ORF45 in KSHV-infected cells
as early as 1 hr post infection (Fig. 3B, lanes 3 and 4). A series of
observations confirmed that the ORF45 detected is only the
virion-associated form and not newly synthesized: (i) infection of
cells with UV inactivated KSHV virions also revealed ORF45 as
seen with intact viruses (data not shown); (ii) treatment of cells with
cycloheximide (a well characterized protein biosynthesis inhibitor)
did not abrogate detection of ORF45 (Fig. 3B, lanes 5 and 6).
Furthermore, treatment of cells with heparin (shown to block
KSHV entry into cells, [29,30]) revealed the complete absence of
ORF45 (Fig. 3B, lanes 7 and 8). These findings thus confirmed
that ORF45 is delivered directly to de novo infected cells
immediately following infection. This combined with the fact that
ORF45 being a tegument component [25,26] is virtually exposed
to the cell environment thus makes it suitably poised to manipulate
the host immune response.
ORF45-null virus triggers an antiviral state in human
fibroblast cells
Due to the several observations that favored a possible role of
ORF45 in antagonism of the host antiviral responses, we went on
to further investigate its potential role. Towards this by genetic
recombineering methodology, we generated an ORF45-null
KSHV recombinant virus (BAC-stop45) from a BAC-cloned
wild-type KSHV genome (BAC36) [31] by introducing a
premature stop codon into the ORF45 coding sequence in the
KSHV genome [32], totally abolishing the functional ORF45
synthesis. The wild-type (BAC36 and revertant virus) and the
mutant BAC DNAs were transfected into 293T cells and subjected
to hygromycin selection that led to the generation of 293T
monolayers stably transfected with either of the BAC DNAs.
Viruses were reconstituted from these monolayer cultures
subsequent to TPA induction [32]. The ORF45 null recombinant
virus system thus provided us with utmost convenience and
reliability to assess the hypothesized role of ORF45 in immune
evasion.
To determine whether cells infected with ORF45-null virus
show altered susceptibility to subsequent virus infection, VSV
plaque formation was assessed in HFF cells infected with intact or
UV-irradiated recombinant viruses, including wild type (BAC36),
revertant (BAC-rev45) and ORF45-null mutant (BAC-stop45),
followed by superinfection with VSV. The results showed that
VSV superinfection produced relatively large numbers of plaques
on mock-infected, BAC36 and BAC-rev45 (including UV-treated)-
infected HFF cells, but few plaques on HFF monolayers earlier
infected with BAC-stop45 or UV-treated BAC-stop45. No plaque
was seen on cells challenged with UV-irradiated HSV-1 or treated
with IFNa (data not shown). To quantitate the VSV superinfection
in cells challenged with various agents, the experiment was
repeated but with a slight modification. Instead of overlaying with
methylcellulose, fresh medium was added to each well after
superinfection with VSV and the VSV released into the medium
was titrated by a plaque assay. As shown in Fig. 4A, VSV titers
from cells infected with intact or UV-irradiated wild type KSHV
(BAC36 and BAC-rev45) were appreciably high being only slightly
lower than those obtained with the mock infected cells. However
HFF cells treated with intact or UV-inactivated ORF45-null
mutant virus (BAC-stop45) showed about a 3 log reduction in
VSV titers.
Susceptibility of wild-type and ORF45 null virus infected HFF
monolayers to VSV superinfection was also addressed by a
Western analysis of the superinfected cells for VSV glycoprotein
(G). As a reflection of the VSV plaque reduction assay, markedly
reduced expression levels of VSV G glycoprotein was revealed in
the cells infected initially with the ORF45-null recombinant virus
Figure 3. KSHV tegument protein ORF45 is delivered into cells
during de novo viral infection. (A) HFF monolayers were mock
infected or infected with gradient-purified KSHV virions. At one hour
post-infection, these cells were subjected to an immunoflorescence
(IFA) by staining with mouse monoclonal antibody (2D4A5) against
ORF45 followed by subsequent treatment with Alexa-488 conjugated
anti-mouse secondary antibody and counterstaining with DAPI. The
DAPI panel shows the nucleus counterstained with DAPI. (B) 293T cells
were infected with gradient-purified KSHV virions in the absence (lanes
3, 4) or the presence of cycloheximide (CHX) (lanes 5 and 6) or heparin
(lanes 7 and 8). After 1 or 2 h post-infection, the unbound viruses were
washed away with low pH buffer. Cell extracts were made and protein
concentration was measured using a Bradford assay kit (Bio-Rad). About
50 mg of the protein extract was run on 4–12% Bis-Tris gels and
expression levels of ORF45 were detected by a western blot using a
specific mouse monoclonal anti-ORF45 antibody. The viral inoculum
lysate (lane 1) and mock-infected cell lysate (lane 2) served as controls.
doi:10.1371/journal.pone.0010573.g003
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Collectively, these findings indicated the ability of an ORF45-
deficient KSHV to trigger an antiviral state convincingly pointing
out the role of ORF45 in subversion of host antiviral defenses.
Antiviral state triggered by ORF45-null virus is associated
with increases in type I IFN signaling
The antiviral state induced by infection with the ORF45-null
recombinant virus, but not with wild type KSHV, thus suggested a
rational association with concomitant increases in the host induced
immune response pathways in host cells. Thus to investigate the
occurrence of this phenomenon, induction levels of specific
immune response genes (inclusive of IFNs, IFN receptors, IRFs
and the IFN inducible proteins) obtained with both the wild-type
and the ORF45 deficient viruses was conveniently and reliably
measured by the employment of a commercial 96-well formatted
SYBR-green based real-time PCR approach (Interferon [IFN] and
Receptor PCR Assay from SABiosciences). Total RNAs collected
6 hours post infection of HFF monolayers with either the BAC36
or the BAC-stop45 viruses were reverse-transcribed to cDNA and
subjected to a real-time PCR. This system by combining the
advantage of real-time PCR with the ability of microarrays thus
allowed for the simultaneous detection of 84 immune response
genes. The expression level obtained for each gene with both the
wild-type and the ORF45-null viruses was normalized to GAPDH.
The fold change for a particular gene of interest was subsequently
calculated by comparing normalized value of that gene between
the two groups (ORF45-null recombinant vs. wild-type). Genes
that revealed a fold change greater than 2 was considered
significant as perceived usually (Supporting Information, Table
S1).
The antiviral defense mechanisms elicited by the host against
the invading virus are predominantly type I IFN mediated [5,15].
Hence in addition to IFNa and its receptor (IFN AR1/AR2)
genes, a majority of the other immune response genes showing a
greater than 2-fold induction with the ORF45-null mutant virus
compared to the wild-type virus were the IFNa inducible
downstream ISGs (Table S1). Among these were the genes with
proven antiviral activities like the myxovirus resistance A (MxA),
29-59 oligoadenylate synthetase 1 (OAS1), the RNA specific
adenosine deaminase (ADAR), IFN stimulated gene (ISG) 56
(IFN-induced protein with tetratricopeptide repeat [IFIT1]), ISG
54 (IFIT2) and ISG60 [15,33–37] as shown in Table S1.
Some of the genes from the above group were subjected
individually to absolute quantification by a real-time PCR
employing specific primer sets (Fig. 5). These included the type I
IFNs and a set of IFN induced downstream ISGs with potent
antiviral effects (MxA, ISG56, OAS1 and protein kinase R
[PKR]). PKR, a major antiviral effector, exerts its antiviral effects
through inhibition of viral translation including in related
herpesviruses like HSV [35]. At 6 hours post-infection, the levels
of IFNb (IFNB) remained nearly unchanged, while the levels of
IFNa1 (IFNA1) and the other antiviral effectors like MxA, ISG 56,
OAS and PKR were only marginally increased in cells infected
with the wild type BAC36 virus compared to mock infected cells
(Fig. 5). However the expression levels of IFNA1 and all the
Figure 4. Induction of an antiviral state by the ORF45-null recombinant KSHV virus. (A) Human foreskin fibroblast (HFF) monolayers were
mock infected (Mock) or infected with the KSHV recombinant viruses, including the wild-type BAC36, UV-irradiated BAC36 (BAC36-UV), BAC-rev45,
UV-irradiated BAC-rev45 (BAC-rev45-UV), BAC-stop45, or UV-irradiated BAC-stop45 (BAC-stop45-UV) at 5 genomes/cell. HFF cells infected with UV-
inactivated HSV-1 (HSV-UV) at an MOI of 5 or treated with IFNa (1000 units/ml) were also included as controls. The following day, the cells were
superinfected with 100 plaque forming units (Pfu) of VSV. Media were collected 24 h later and VSV titers were determined by a standard plaque
assay. Data are the average of the results from three experiments. Error bars represent standard deviation. (B) HFF monolayers mock infected or
infected with BAC36 (wild-type, wt), BAC-rev45 or BAC-stop45 viruses were super infected as above with VSV. Twenty-four hours postinfection, cell
lysates were collected and analyzed by a Western blot for expression levels of KSHV latent nuclear antigen (LANA), KSHV ORF45, VSV G glycoprotein
and b-actin (loading control) employing specific antibodies.
doi:10.1371/journal.pone.0010573.g004
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elevated in cells infected with the ORF45 null virus (with nearly a
4-fold increase seen with ISG56) (Fig. 5) compared to the BAC36
virus infected cells. The increased upregulation of ISG56 coincides
well with the fact that it remains the most highly upregulated gene
following IFNa induction [16]. The upregulation patterns of the
type I IFNs and the downstream ISGs more or less mirrored each
other in both the assays. Thus, it could be pointed out that the
antiviral state induced by the ORF45-null mutant virus was
associated in parallel with an induction of type I IFN mediated
antiviral immune response genes.
A surprising observation is the low level activation of IFNb
following infection with the stop45 mutant virus (Table S1 and
Fig. 5). It has been earlier shown in transgenic mouse models that
in early phase immune response there is a predominance of IFNb
which subsequently gets replaced with IFNa [38] which could be
mimicking our present observation which was observed only
6 hours post infection. The decreased potency of IFNb in
activating itself compared to its effect on IFNa combined with
the finding that IFNa is potent in only activating itself following
the initiation of the positive feedback loops have has been given as
possible reasons [38].
Ectopic expression of ORF45 in human fibroblast cells by
lentivirus vector alleviates antiviral responses
The loss-of-function assays clearly demonstrated the significant
role of ORF45 in evasion of the host antiviral response during the
initial stages of viral infection. Next, we examined whether ectopic
expression of ORF45 in cells affects the susceptibilities of cells to
VSV infection. HFF cells were transduced with the lentiviral
vector expressing ORF45 (lenti-ORF45+) or with an empty
lentiviral vector (lenti-empty) or with a vector in which ORF45
was inserted in the opposite orientation (lenti-ORF45-). Mock
transduced HFFs were used as control. Transduction efficiencies
were estimated to be more that 90% by examining green
fluorescent protein (GFP) expression under fluorescent microscopy
(data not shown) and successful lentivirus transduction was
confirmed by Western blot analysis in which ORF45 expression
was detected only in cells transduced with the lenti-ORF45+
(Fig. 6A). VSV plaques were clearly seen after superinfection in
cells not transduced with lentivirus while cells transduced with the
lentiviruses lenti-empty or lenti-ORF45- revealed no VSV plaque
(Fig. 6B) indicating that the transduced lentiviral particles are
capable of eliciting an immune response. In contrast, cells
transduced with ORF45-expressing lentivirus (lenti-ORF45+)
exhibited small but visible VSV plaques (Fig. 6B). Quantitation
of VSV superinfection revealed a VSV titer of 4610
8 pfu/ml for
non-transduced cells, whereas cells transduced with lenti-empty or
lenti-ORF45
- yielded less than 4610
4 pfu/ml (Fig. 6C), suggesting
that lentiviral infection interferes with subsequent VSV infection,
consistent with the effect of HIV on VSV superinfection in
monocytes [39]. The VSV titer from cells transduced with lenti-
ORF45+ was 7.5610
7, slightly less than that of mock-transduced
cells, but significantly higher than that of cells transduced with
lentivirus not expressing ORF45 (Fig. 6C). Based on these data, we
conclude that lentiviral infection of HFF cells induced an antiviral
response, so that VSV titers were lower in lentiviruses-transduced
cells than non-transduced cells (4610
4 vs. 4610
8); ectopic
expression of ORF45 alleviates the antiviral response and restores
the infectivity of VSV (7.5610
7 vs. 4610
8). Together, the loss-of-
function and gain-of-function assays indicate that ORF45 is potent
to antagonize the host antiviral response triggered by a viral
infection.
IRF-7 critically contributes to the innate immune
response subsequent to primary KSHV infection
With ORF45 being shown to be the active KSHV virion
component that effectively evades the host immune response
combined with the earlier finding that it inactivates IRF-7, we
finally wanted to investigate the role of IRF-7 in the induction of
immune responses to the incoming KSHV and address the
question if wild type KSHV indeed uses ORF45 to target IRF-7 in
order to disarm elicited host antiviral responses. To this end, we
attempted to knockdown the endogenous IRF-7 expression in
HFF cells through a short-hairpin RNA (shRNA) approach. A
Mission shRNA gene set against human IRF-7 gene was
purchased from Sigma-Aldrich. The Mission shRNA system is a
lentiviral vector-based RNA interference library against annotated
human genes, which generates siRNAs in cells and mediates gene
specific RNA interference for extended periods of time. The IRF-7
shRNA set consisted of 5 (clone #s 1-5) individual shRNA
lentiviral vectors against different target sites of the IRF-7 mRNA
Figure 5. Evaluation of type I interferon (IFN) and downstream IFN stimulatory gene (ISG) transcription. HFF cells seeded in 6-well
plates were infected with the KSHV wild-type (BAC36) or the ORF45-null recombinant (stop45) viruses. Six hours post-infection, cells were lysed with
Trizol reagent and total RNAs isolated. Residual DNA contamination was eliminated by subsequent treatment with Turbo DNase I and the RNA was
subsequently reverse transcribed to cDNA. The cDNA samples were then subjected to an absolute real-time PCR based quantification with specific
primers for IFNA1, IFNB and selected downstream antiviral effector genes (ISG56, MxA, PKR and OAS). The amounts of mRNA were quantitated based
on comparison with the standard templates of cloned cDNAs of known copy number following which the expression levels were normalized to
GAPDH.
doi:10.1371/journal.pone.0010573.g005
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shRNAs and subjected to puromycin selection. The endogenous
expression levels of IRF-7 in mock-transduced HFF cells were very
low as shown by a Western analysis (Fig. 7A). The HFF cells that
were transduced with a lentiviral ‘‘control’’, (a shRNA sequence
that activates the RNAi pathway without targeting any of the
known human genes) resulted in increased levels of IRF-7 (Fig. 7A).
This is consistent with previous studies that have shown that
shRNA encoding vectors including shRNAs delivered by lentivi-
ruses [40,41] are capable of IFN activation that could generate a
feedback loop resulting in increased IRF-7 levels. HFF monolayer
cultures stably transduced with IRF-7 shRNA clone #1 gave
almost a total knockdown of IRF-7, while cells transduced with
clone #s 3 and 4 also gave appreciable reduction of IRF-7
(Fig. 7A). Thus these HFF monolayers giving noticeable IRF-7
knockdown (clone #s 1, 3, 4) along with the cells transduced with
the ‘‘control’’ shRNA lentivirus were subsequently infected with
either the BAC36 or the ORF45-null recombinant viruses
followed by VSV superinfection as described above. The HFF
cells that were transduced with IRF-7 shRNA clones 1, 3 and 4
and infected with ORF45-null mutant virus failed to induce any
immune response as evidenced by the obvious susceptibility of
these cells to superinfection with VSV. This was indicated by a
Western blot revealing elevated expression levels of the VSV G
glycoprotein in these cells (Fig. 7B). In contrast, the cells that
transduced with the ‘‘control’’ shRNA and infected with the same
virus (ORF45-null) were able to develop an antiviral state as
manifested by the failure to be superinfected with VSV. The VSV
G protein levels in IRF-7 shRNA (clones 1, 3 and 4) transduced
and ORF45-null virus infected HFF cells were however found
comparable to those in the cells transduced with the ‘‘control’’
shRNA transduced and infected with wild type KSHV (BAC36)
(Fig. 7B). Additionally, the similar VSV susceptibilities were
observed in BAC36 infected cells in the presence (with control
Figure 6. Ectopic expression of KSHV ORF45 in lentivirus transduced HFF cells permits VSV superinfection. HFF cells seeded in 24-well
plates were mock-transduced or transduced with the lentiviruses expressing ORF45 (lenti-ORF45+) or not expressing ORF45 (lenti-empty and lenti-
ORF45- [where the ORF45 sequence was inserted in the opposite direction]) as controls. (A) Cell lysates of lentivirus transduced cells were analyzed
with Western blot with antibodies against ORF45 and GFP to ensure the success of transduction. The same blot was also probed with b-actin
antibody for an equal loading control. (B) At 24 h post-tranduction, cells were superinfected with VSV, overlayed with 1% methylcellulose in media
and stained with 0.1% crystal violet 24 h later for visulalization of plaques. Images were taken under 12x dissection microscopy. Some of the plaques
in the mock transduced and the Lenti-ORF45+ transduced cell monolayers are indicated by arrows for easy visualization. (C) Quantitation of VSV
super-infection. Parallel experiments were performed as above. After VSV superinfection, each well was supplemented with 1 ml fresh DMEM instead
of being overlayed with methylcellulose. Media were collected 24 h later and VSV titers in the supernatant medium were determined by a standard
plaque assay.
doi:10.1371/journal.pone.0010573.g006
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Taken together, these data prove the vital role of IRF-7 in the
development of an antiviral state that inhibits VSV superinfection
and also indicate that ORF45 is very much effective in targeting
this immune response by inactivating IRF-7 amounting to a total
knockdown as mimicked with the specific shRNAs.
Discussion
Host antiviral responses and viral immune evasion
Primary infection of a cell with a herpesvirus is initiated with the
attachment of the viral glycoproteins to the host cell surface. This
is followed by the release of the viral components (tegumented
capsids) into the cell environment for their transportation to the
nucleus and the subsequent onset of viral replication. The host cell
however immediately responds to the viral invasion by generation
of specific antiviral immune responses [5,6]. This predominantly
involves the induction of type I IFNs (IFN-a/b) which trigger the
transcription of a group of downstream IFN stimulated genes
(ISGs) and production of effector proteins [5,6,15]. These effector
proteins exert their functions through multiple pathways aiming to
inhibit the viral transcription/translation also enhancing the
degradation of the viral mRNA, ultimately helping the cell to
eradicate the virus [15].
Such elicitation of immune responses against the invading virus, is
seen in related herpesviruses like HSV and HCMV, wherein the
binding of glycoproteins gD and gB respectively to the cell surface
receptors induce type I IFN signaling followed by downstream
multiple ISG synthesis [7,8]. In KSHV too, infection of cultured
fibroblast cells with soluble envelope glycoprotein K8.1 was found to
induce a type I IFN response evidenced by increased transcription of
both IFNb and downstream ISGs with antiviral effects like 29-59
OAS and ISG 54 [9]. This effect was also substantiated by our
present study that illustrated proportionate increases in the
transcription of IFNA1 promoter following infection of HEK
293T cells with increasing inputs of KSHV K8.1 glycoprotein.
In spite of the type I IFN enhancing effect of KSHV gpK8.1,
the virus was able to effectively disarm this response thus assuring
the success of its infection. An earlier gene profiling study
examining the up regulation of cellular genes following primary
KSHV infection of cultured cells, indicated the clear absence of
any increased transcription of both the type I IFN genes and its
receptors [10]. Further infection of cells with UV treated KSHV
virions revealed almost undetectable levels of IFNb transcripts
(inclusive of the downstream ISG54) [9] and failed to activate the
IFNA1 promoter transcription activity (our present study). More
importantly infection of cultured fibroblast cells with UV-treated
KSHV virion particles [9] or with untreated/UV treated wild type
KSHV clearly resulted in abrogation of the antiviral state
illustrated by subsequent superinfection of cells with an indicator
virus, VSV (our present study). Taken together, the preceding
observations obviously indicate the role of a possible virion
component in quickly and efficiently disarming the initial host
elicited immune response. Interestingly in HCMV and RhCMV,
virion components were found to counteract the initially generated
host immune response [11–13].
Role of ORF45 in antagonizing host antiviral responses
We had earlier shown that KSHV tegument protein ORF45
inhibits both phosphorylation and nuclear translocation of IRF-7
needed for its activation and for the substantial induction of type I
IFNs [27]. In the present study, we employed genetic approaches,
both loss-of-function and gain-of-function, to investigate the role of
ORF45 in the immune evasion pathway. We found that KSHV is
able to prevent activation of host antiviral defense mechanisms
upon infection, as cells infected with wild type KSHV were
permissive to superinfection by VSV. In contrast, infection of cells
with ORF45-null viruses, both untreated and UV-irradiated,
resulted in induction of an antiviral state hence markedly
decreasing the susceptibility of the cells to superinfection with
VSV. This correlated with a higher level of expression of IFNa,
Figure 7. Interferon regulatory factor-7 (IRF-7) critically contributes to the immune response following primary KSHV infection. (A)
Knockdown of IRF-7 expression by short-hairpin (shRNA)-mediated silencing. Five shRNA constructs (clone #s 1-5) each consisting of specific shRNA
sequences in pLKO.1-puro plasmids against different target sites of IRF-7 mRNA along with a non-targeting ‘‘control’’ shRNA that activates the RNAi
pathway without targeting any known human gene were transduced into HFF cells in the presence of polybrene. Transduced HFF cells were selected
with puromycin (2 mg/ml) to allow for the generation of HFF monolayers expressing stable and long term downregulation of IRF-7. The efficiency of
the different shRNA clones in knocking down expression of IRF-7 as compared to the ‘‘control’’ was tested by a Western blot (WB) performed on cell
extracts with a rabbit polyclonal antibody against IRF-7 and subsequent probing with b-actin (equal loading control). Endogenous expression levels
of IRF-7 in mock transfected HFF cells was also checked. (B) HFF monolayers expressing efficient down regulation of IRF-7 (clone #s 1, 3 and 4) along
with the ‘‘control’’ transduced HFF cells were infected with the wild-type (BAC36) and the ORF45-null (BAC-stop45) recombinant viruses and
subsequently super infected with VSV. Twenty four hours post VSV infection, cell lysates were collected and by a Western blot were analyzed for
expression levels of KSHV latent nuclear antigen (LANA), KSHV ORF45, VSV G glycoprotein and b-actin (loading control) employing specific antibodies.
doi:10.1371/journal.pone.0010573.g007
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IFNa responsive downstream effector ISGs were the proteins
predominantly associated with major antiviral activities like MxA,
OAS, ADAR and IFIT1 (ISG56) [15,33-37]. Significance needs to
be attributed to this finding given that activated MxA effectively
binds and traps incoming viral nucleocapsids targeting them
towards degradation, thus eradicating incoming viral complexes
even before start of viral gene transcription [36]. Taken together,
our study results indicate the importance of down regulation of
both type I IFN and its responsive downstream ISGs following
primary KSHV infection.
In addition to the loss-of-function study, we also attempted to
establish the role of ORF45 in evasion of immune responses
through ectopic expression of ORF45. ORF45 expressing
lentiviral particles upon transduction of fibroblast cells produced
a characteristic ablation of an antiviral state evidenced by
increased susceptibility of cells to subsequent VSV superinfection
contrasting to the increased resistance offered to VSV by empty
lentiviral particles or particles encoding for a non functional
ORF45. Thus the extraneous expression of ORF45 by functioning
as a gain of function assay, together with the loss-of-function assays
employing ORF45-null mutant virus, demonstrated a crucial role
of KSHV ORF45 in evading the host immune responses. It is
worthwhile to note that this gain of function study revealed an
additional function to block interferon responses. In KSHV
infection, the ORF45 protein is present before cell gets significant
amplification of the interferon response. However, with lentiviral
infection, interferon responses along with IRF activation have
initiated prior to ORF45 expression, but ORF45 is still able to
block the interferon response. This notion has been proven by an
shRNA-mediated IRF-7 knockdown study in HFF cells (Fig. 7)
indicating that that ORF45 is able to disarm an antiviral response
that has been already elicited by lentiviral infection.
The master regulator of IFN-dependent immune
responses is hit by a master viral inhibitor
KSHV uses an array of mechanisms to evade host antiviral
responses including IFN signaling pathways [42,43]. Besides
ORF45, other immune evasion mechanisms of KSHV involving
the type I IFN pathway have been described. The KSHV genome
encodes four IRF homologues, designated vIRFs. Some of the
vIRFs such as vIRF-1,vIRF-2 and vIRF-3 have been shown to
inhibit cellular IRF pathways through dominant negative effects
interfering with the activities of IRF-3 or IRF-7 [44–49]. In
addition, KSHV also encodes for an IL-6 homolog, the vIL-6
shown to overcome IFN-mediated cell growth arrest [50].
Recently, the product of the KSHV ORF10 has also been shown
to block the type I IFN signaling [51]. An immediate-early protein,
RTA/ORF50 was also reported to suppress IRF-7 activation by
targeting IRF-7 gene products for proteosome-mediated degrada-
tion [52]. The redundancy of counter-IFN activities encoded by
KSHV emphasizes the importance of antagonism of the type I
IFN signaling to the KSHV life cycle. Despite this redundancy,
our loss-of-function and gain-of-function studies positively indicate
that ORF45 is critical in the evasion of antiviral responses
following primary infection. The profound role of ORF45 in
immune evasion may rest in two unique features of ORF45.
First, ORF45 targets a fundamental regulator, which is of
paramount importance of both innate and adaptive immunity.
IRF-7 is a master regulator of type I IFN-dependent immune
responses. Recent studies employing IRF-7 deficient (IRF-7
2/2)
mice demonstrated that type-1 IFN induction is severely impaired
in the deficient mice and these mice are vulnerable to viral
infection [20,21]. Accordingly the low level of endogenous IRF-7
(in uninfected cells) subsequent to the viral infection gets activated
by phosphorylation and translocates to the nucleus mediating the
initial phase induction of type I IFN. This in turn further activates
IRF-7 initiating a positive feedback loop for the substantially
increased late phase induction of type I IFNs. Thus by vitally
participating in both the initial and the late phases of IFN
secretion, IRF-7 emerged as the only known IRF significantly
modulating the host innate immunity [20,21]. Hence it was not
surprising that IRF-7 was also one of the genes significantly
elevated following infection with the ORF45 null recombinant
virus in our present study.
The importance of IRF-7 in host cell antiviral responses was
again proved in our shRNA-mediated IRF-7 gene silencing
experiment. Cells with the IRF-7 shRNA sequences were not able
to develop antiviral responses upon infection with ORF45-null
mutant virus as compared to control cells (with no IRF-7
knockdown) in which infection with ORF45-null virus conferred
cell resistance to VSV superinfection. This finding suggested the
following: (i) critical contribution of IRF-7 towards the innate
immune response as shown earlier [20,21] (ii) negligible contribu-
tion of other IRFs including IRF-3 towards induction of the type I
IFN responses.
Given the role of endogenous IRF-7 it might well be suggested
that KSHV ORF45 could directly interact with and inhibit the
activation of the low level endogenously expressed IRF-7 hence
preventing even the initial induction of type I IFNs and thus the
subsequent initiation of the positive feedback loop for the
increased late phase induction of IFNs. More recently IRF-7
was also found essential for the type I IFN induction mediated by
the TLR9 subfamily of proteins [20,21]. Viral invasion of a cell
activates TLR9 that subsequently recruits the adaptor protein,
MyD88. This adaptor protein through exclusive activation of IRF-
7, results in type I IFN secretion, governing the induction of CD8
+
T-cell responses contributing to adaptive immunity in DCs. It has
been suggested that DCs could be infected with KSHV and could
play vital roles in the transmission and pathogenesis of KSHV
[22,23], though further studies are underway. Thus it is tempting
to speculate that ORF45 through its targeting of IRF-7 could play
vital roles in evasion of both innate and adaptive immunity.
Second, unique among the KSHV encoded genes contributing
to IFN mediated immune evasion as described earlier, ORF45 is
the only known virion component abundantly present in the
KSHV virions localized to the tegument [25,26]. In the present
study, we showed the presence of ORF45 in infected cells at very
early time points (as early as 1 hour) following viral infection with
both wild-type and UV treated KSHV virions. Thus it could be
reasoned that ORF45 being a tegument component gets
immediately delivered de novo to infected cells hence is quickly
and potently able to exert its effect. This combined with its
potential to inactivate IRF-7, obviously places this protein at a
much higher pedestal compared to others in immune evasion
immediately following primary viral infection. This not only allows
KSHV to establish a fruitful infection but also lays the foundation
for further progression of the viral life-cycle. Interestingly, periodic
viral reactivation from latency also would come under host
surveillance which again needs to be effectively evaded. ORF45
being an immediate-early protein [24] is produced very early
following lytic reactivation, hence is again favorably poised to
encounter this immune response too.
Other implications from ORF45-mediated immune
evasion
Evasion of host antiviral responses is not only important for viral
propagation, but also linked to viral tumorigenesis. Several
Immune Evasion by KSHV ORF45
PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10573features of IFNs suggest their close inter relationship with tumor-
suppressor pathways: (i) IFNs possess cell growth suppression
activities [53]; (ii) type I IFNs serve as a bridge between innate and
adaptive immune systems which have elaborate mechanisms to
eliminate virus infected and cancer cells [54]; (iii) Some IRFs, such
as IRF-3 and IRF-1, act as tumor suppressor genes [55–57];
(iv)type I IFNs can boost the response of p53 to stress signals. It has
been shown that p53 gene induction by IFN a/b contributes to
tumor suppression, linking IFN pathways directly to host tumor
suppression pathways [58]. Thus, evasion of host immunity and
tumorigenesis might be ‘‘two sides of the same coin’’ [42] and
ORF45 might also contribute to KSHV-associated tumorigenesis
by inhibiting IFN signaling.
KSHV-infected cells were also found permissive for superinfec-
tion by other viruses in our study, which may also have
implications for the viral pathogenicity. HIV-1 is a known risk
factor for KS and reciprocal interaction between HIV-1 and
KSHV has been found in cells co-infected with these viruses. Such
interaction may have impact on KS development and AIDS
progression [59–61]. Co-infection of KSHV with other viruses
such Epstein-Barr virus is also very common in PEL cells [62].
Overall, the strategy of antiviral immune evasion by ORF45 may
thus be directly associated with KSHV pathogenicity.
Materials and Methods
Cells, viruses, plasmids and reagents
BCBL-1, a latent KSHV-infected primary effusion lymphoma cell
line [63] was maintained in RPMI 1640 medium. Human cervical
carcinoma derived cell line (HeLa) [27], human embryonic kidney
(HEK) 293T [32] and human foreskin fibroblasts (HFF24441) cells
[64] were maintained in Dulbecco’s modified Eagle’s medium
(DMEM). All cultures were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and antibiotics.
Sucrose gradient-purified HSV-1 KOS strain was kindly
provided by Drs. Gary Cohen and Roselyn Eisenberg (University
of Pennsylvania). A portion of these virions were also subjected to
UV irradiation employing an UV Stratalinker 2400 instrument
(Stratagene) for a period of time sufficient to reduce the viral titers
by a factor of 10
5. For production of KSHV virions, BCBL-1 cells
were induced with TPA for 5 days. Post induction, the medium
was collected and cleared by centrifugation to remove cells and cell
debris. The supernatant was filtered through 0.45-mm filters.
Virions were subsequently concentrated and gradient purified
from the supernatant as per established protocols [25,26]. A
portion of KSHV virions were also irradiated by UV treatment as
done for HSV. VSV (Indiana strain) was obtained from Dr.
Ronald Harty (University of Pennsylvania). The virus was
propagated and titers were determined by a standardized plaque
reduction assay on Vero cells. Sendai viruses were bought from
Charles River Laboratories (Wilmington, MA).
The BAC36/DH10B, containing the entire KSHV genome as a
bacterial artificial chromosome (BAC) was obtained from Dr. S. J.
Gao (University of Texas, San Antonio) [31]. Plasmids pGL-
IFNA1, pCR3.1-IRF-7 and pCR3.1-ORF45 have been earlier
described [27]. Purified recombinant K8.1 and gB proteins
produced in a baculovirus expression system were kindly provided
by Dr. Bala Chandran (University of Kansas Medical Center)
[29,65]. Human IFNa was a gift from Hoffmann-La Roche Inc.
(Nutley, NJ). 12-0-tetradecanoyl-phorbol-13-acetate (TPA), sodi-
um butyrate and polybrene (Hexadimethrine Bromide) were
purchased from Sigma (St. Louis, MO). Hygromycin was
purchased from Roche Inc. (Indianapolis, IN) and Turbo DNase
I was obtained from Ambion (Austin, TX).
Production of BAC36 wild-type and ORF45-null
recombinant KSHV viruses
The detailed protocol for generation of recombinant KSHV
with bacterial artificial chromosome (BAC) technology is described
in Zhou et al [31]. To generate an ORF45-null mutant virus, we
employed a two-step replacement procedure using the wild-type
KSHV cloned into a BAC (BAC36) as the template [32]. In the
first step, ORF45 coding sequence from the BAC36 genome was
replaced with Kan/SacB double selection cassette by genetic
recombineering. In the second step, a revertant (BAC-rev45) was
generated by replacing the Kan/SacB cassettes with wild type
ORF45 coding sequence. Similarly, an ORF45-null recombinant
(BAC-stop45) virus was also generated by the introduction of a
premature stop-codon (by replacing the 8th codon [TCG] in the
ORF45 coding sequence to a stop codon, TAG) [32]. Wild-type
BAC36, BAC-rev45 and BAC-stop45 DNAs were prepared using
the Large Construct Kit (Qiagen). These freshly prepared BAC
DNAs were transfected into 293T cells with the Qiagen Effectene
transfection reagent and stable BAC-293T monolayers were
generated through hygromycin selection as detailed earlier [32].
To produce recombinant viruses, monolayers were treated with
20 ng/ml of TPA and 0.3 mM sodium butyrate for induction of
viral lytic replication. At 4–5 days post-induction, culture
supernatants were collected and filtered through 0.45 mm filters.
Virions were pelleted at 100,000 g for 1 h on a 25% sucrose
cushion with a Beckman SW28 rotor. The pellets were dissolved in
PBS to 1% of the original volume and the viral aliquots frozen at
280uC. Genomic copy number was subsequently estimated by a
real-time PCR.
Real-time PCR of viral genomic DNA
Concentrated viruses were first treated with Turbo DNase I at
37uC for 1 h to remove any contaminating DNA outside the viral
particles. Viral DNA was liberated by subsequent digestion with
lysis buffer (A) and proteinase K (supplied with the DNeasy tissue
kit, Qiagen) and extracted with phenol-chloroform. Extracted
DNA was precipitated with ice-cold ethanol, and the final DNA
pellet was dissolved in Tris-EDTA buffer. Copy numbers of
KSHV genomic DNA were estimated by a real-time DNA PCR
with a Roche LightCycler using the LightCycler FastStart DNA
Master
Plus SYBR green kit with primers directed to LANA [66].
Viral DNA copy numbers were calculated from external
standards of known concentrations of BAC36 DNA. A serial
dilution of a known amount of BAC36 DNA was used to
construct a standard curve and copy numbers of KSHV genome
(for downstream infection of cells) were determined by compar-
ison to this standard curve.
Plaque reduction assay
HFF2441 cells were seeded in 24-well plates to obtain a near
confluent monolayer the next day. These monolayers were either
mock-infected or infected with (i) intact/UV-irradiated KSHV
virions (ii) intact/UV-irradiated KSHV recombinant viruses
(BAC36 wild-type, BAC-rev45 and BAC ORF45 null [BAC-
stop45]) at a multiplicity of infection (MOI) of 5 or 50 in serum-
free DMEM for 1 h followed by replacement with DMEM
containing 5% FBS. IFNa was added to mock-infected samples at
1000 units/ml. After 24 h, monolayers were super infected with
approximately 100 plaque forming units (Pfu) of VSV, followed by
replacement with DMEM containing 1% methylcellulose. Cells
were fixed and stained with 0.1% crystal violet 24 h later for
convenient visualization of the VSV induced plaques. In some
cases, instead of overlaying with methylcellulose, fresh medium
Immune Evasion by KSHV ORF45
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10573was added and cultures incubated for an additional 24 hours.
Subsequent to this, the VSV titers in the supernatant medium
were estimated by a standard plaque assay.
Immunoflorescene assay (IFA)
For immunofluorescence analysis, HFF cells grown on cover-
slips were infected with KSHV followed with or without
superinfection with VSV. Infected cells were fixed with 3%
paraformaldehyde in PBS for 20 min and subsequently permea-
bilized with 0.1% Triton X-100 in PBS at 4uC for 10 min.
Permeabilized cells were blocked with PBS (with 2% BSA) for
30 min at room temperature. Cells infected first with KSHV
followed by VSV superinfection were subjected to a double-
labeled IFA with mouse monoclonal anti-LANA (kindly provided
by Bala Chandran) and rabbit anti VSV-G antibodies (Sigma).
Alexa 488 conjugated goat anti-mouse IgG and Alexa 568
conjugated goat anti-rabbit IgG (Molecular Probes-Invitrogen
Corp., Carlsbad, CA) were used as the respective secondary
antibodies and cells were subsequently examined under a confocal
microscope. On the other hand, cells infected only with KSHV
were subjected to an IFA with a mouse monoclonal anti-ORF45
antibody followed by staining with Alexa 488 conjugated goat
anti-mouse IgG and examined under a confocal microscope.
Luciferase assay
Subconfluent 293T cells grown in 24-well plates were transfected
with pGL-IFNA1 (a luciferase report vector driven by the IFNA1
promoter), an IRF-7 expressing plasmid (pCR3.1-IRF-7) cloned into
ap C R 3 . 1v e c t o ra n dap R L - T Kr e p o r t e r( Renilla luciferase as an
internal control) plasmid by employing a Qiagen Effectene
transfection kit. Twenty four hours subsequent to transfection, the
cells were infected with the indicated viruses at specified MOI or
with purified KSHV envelope glycoprotein K8.1 or gB at increasing
inputs of 1 and 5 mg/ml respectively. Six hours post infection, cell
lysates were collected and the luciferase assay was performed with
the Promega’s Dual-luciferase assay kit (Promega, Madison, WI).
Western blot analyses
Monolayers of (i) 293T cells infected with gradient purified
KSHV virions (ii) HFF cells infected with BAC cloned
recombinant viruses (including the BAC36, BAC-rev45, BAC-
stop45) followed by VSV superinfection at indicated time points
were washed twice with ice-cold PBS and lysed with ice-cold lysis
buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 30 mM NaF,
5 mM EDTA, 10% glycerol, 40 mM a-glycerophosphate, 1 mM
phenylmethylsulfonyl fluoride [PMSF], 1% Nonidet P-40, 1 mM
sodium orthovanadate) supplemented with protease inhibitor
cocktail (Roche). The cell lysates thus prepared were homoge-
nized, clarified by high-speed centrifugation at 4uC and subse-
quently run on SDS-PAGE 8 to 12% Bis-Tris gels (Invitrogen) and
transferred onto nitrocellulose membranes. These membranes
were blocked in 5% dried milk in 16 phosphate-buffered saline
plus 0.2% Tween 20 and subjected to a western blot using
antibodies appropriate for the different proteins. Thus whole cell
lysates prepared from (i) KSHV infected 293T cells were probed
with mouse monoclonal anti-ORF45 antibody (ii) BAC cloned
recombinant KSHV virus infected HFF cells were probed with
mouse monoclonal anti-ORF45 [25,26], rabbit polyclonal anti-
LANA, rabbit polyclonal anti-VSV G (Sigma) along with mouse
monoclonal anti-beta actin (Sigma) antibodies. Anti-rabbit or anti-
mouse IgG antibodies conjugated to horseradish peroxidase
(Amersham) were used as the respective secondary antibodies
followed by an enhanced chemiluminescence system (ECL) for the
final detection of the antibody-antigen complexes.
Lentivirus-mediated expression of ORF45 in human
fibroblast cells
Standard protocols were followed to generate HIV-based
lentivirus expressing KSHV ORF45 [67]. The coding sequence
of ORF45 was excised from pCR3.1-ORF45 and cloned into a
lentivirus transfer vector. Two types of clones with both
orientations were obtained. Clone 14, in which ORF45 was
inserted with sense orientation, was used to generate lenti-
ORF45+ that expresses ORF45 upon transduction. Clone 1, in
which ORF45 was inserted with opposite orientation, was used to
generate lenti-ORF45- that does not express ORF45 and hence
was used as the negative control.
Lentivirus particles were generated in 293T cells using transient
transfection with three plasmids: transfer vector containing
ORF45 (either in the sense or in the opposite orientation),
packaging plasmid pCMV8.2DR, envelope plasmid pVSVG [67].
Lentivirus released into the supernatant were harvested at 72 h
post-transfection, centrifuged (5006g for 10 min at 4uC), filtered
through a 0.45 mm filter to ensure removal of any non adherent
cells and stored in aliquots at 270uC. Virus titers were
subsequently determined by addition of serially dilutions of the
lentiviral stocks to monolayers of HeLa cells grown in 96 well plate
and positive infection determined by fluorescence microscopy.
HFF cells seeded in 24-well plates were transduced with the
titered lentiviral stock in the presence of 4 mg/ml polybrene. Plates
were centrifuged at 1,5006g for 90 min at room temperature to
enhance the transduction process. Subsequently the transduced
cells were washed with medium and cultured for an additional
24 h. After 24 h, monolayers were infected with approximately
100 plaque forming units (Pfu) of VSV and overlayed with 1%
methylcellulose in media or in parallel supplemented with fresh
DMEM. VSV viral titers were then obtained by standardized
plaque assays as described earlier.
Evaluation of transcription of type I IFNs and ISGs
HFF cells seeded in 6-well plates were either mock infected or
infected with the KSHV wild-type (BAC36) or the ORF45-null
recombinant (stop45) viruses at 50 genomes/cell. Six hours post
infection, cells were lysed with Trizol reagent (Invitrogen) and total
RNAs isolated according to the manufacturer’s protocol. Residual
DNA contamination was eliminated by subsequent treatment with
Turbo DNase I (Ambion). cDNA was generated from total RNA
with the SuperScript First-Strand Synthesis System (Invitrogen),
priming with random hexamers. The cDNA thus obtained was
analyzed by a commercial system employing a 96-well formatted
SYBR-green based real-time PCR approach (Interferon [IFN] and
Receptor PCR array [SABiosciences]) to compare the expression
levels of type I IFNs and the type I IFN induced ISG levels in the
cells infected with the BAC-stop45 viruses compared to those
infected with BAC36. Herein the cDNA was mixed with a SYBR-
green containing mix and aliquoted into wells of a 96-well plate
(each well containing pre dispensed gene specific primer sets) and
subjected to a real-time PCR by running on an ABI Prism7700
(Applied Biosystems) according to the manufacturer’s instructions.
This system combines the advantage of real-time PCR with the
ability of microarrays hence allowing for the simultaneous
detection of 84 immune response genes. The expression level
obtained for each gene with both wild-type and the stop45 viruses
was normalized to GAPDH. The fold change for a particular gene
of interest was subsequently calculated by comparing normalized
value of that gene between the 2 groups (ORF45 null recombinant
vs. wild-type) as per the manufacturer’s instructions. Genes that
revealed a fold change greater than 2 were considered significant.
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tion by a real-time PCR to analyze the levels of type I IFNs and
downstream antiviral effectors (ISG56, MxA, PKR and OAS)
using primers specific for each gene as below:
(i) IFNA1+ (59-TGATGAATGCGGACTCCATCT-39)
IFNA1- (GACAACCTCCCAGGCACAAG-39)
(ii) IFNB+ (59-GCCAGAGGAATATGTCAGCTTT-39)
IFNB-(59-GCAAAGTGATCCCCCAAATA-39)
(iii) ISG56+ (59-AGGACTTCTAGCCTCGAGAACTT-39)
ISG56- (59-GCTCCAGACTATCCTTGACCTG-39)
(iv) MxA+ (59-ATCCTGGGATTTTGGGGCTT-39)
MxA- (59-CCGCTTGTCGCTGGTGTCG-39)
(v) PKR+ (59-TCTACGCTTTGGGGCTAA-39)
PKR- (59-GCCATCCCGTAGGTCTGT-39)
(vi) OAS+ (59-AACTGCTTCCGACAATCAAC-39)
OAS- (59-CCTCCTTCTCCCTCCAAAA-39)
(vii) GAPDH+ (59-AGCCACATCGCTCAGACAC-39,
GAPDH- (59-GCCCAATACGACCAAATCC-3’)
Absolute quantification was performed with the Roche Light-
Cycler using the FastStart DNA Master
Plus SYBR Green Kit.
The amounts of mRNA were quantitated based on comparison
with the standard templates of cloned cDNAs of known copy
number following which the expression levels were normalized to
GAPDH.
Knockdown of IRF-7 expression using shRNA mediated
silencing
Mission shRNA gene sets against the human IRF-7 were
purchased from Sigma-Aldrich. This set consisted of five
individual shRNA lentiviral vectors in pLKO.1-puro plasmids
against different target sites of IRF-7 (with clone IDs NM_001572
-1213s1c1, -1156s1c1, -1573s1c1, -329s1ca, -1686s1c, for conve-
nience sake referred to as clone #s 1-5). A ‘‘control’’ vector,
SHC002 (a non-targeting shRNA that activates the RNAi
pathway without targeting any known human gene) was also
purchased (Sigma-Aldrich). Lentiviral stocks encoding the shRNA
of interest were prepared by transient cotransfection of 293T cells
with the shRNA encoding transfer vector and the two packaging
vectors (pHR’8.2DR and pCMV-VSV-G) at a stipulated ratio of
4:3:1 respectively. Three days post-transfection, lentiviruses
released into the medium were collected, harvested by centrifu-
gation (5006g for 10 min at 4uC) and filtered through a 0.45 mm
filter to ensure removal of cell debris and floating cells. Confluent
monolayers of HFF cells were transduced with the shRNA
encoding lentivirus stocks in the presence of polybrene (8 mg/ml).
Transduced cells were selected with puromycin (2 mg/ml) to allow
for the generation of HFF monolayers expressing stable and long
term downregulation of IRF-7. Efficacies of the individual
shRNAs in knocking down IRF-7 expression were evaluated by
a western blot performed on the whole cell extracts probed with a
rabbit polyclonal anti-IRF-7 antibody. HFF monolayers express-
ing efficient down regulation of IRF-7 were infected with the wild-
type (BAC36) and the ORF45-null (BAC-stop45) recombinant
viruses. Twenty-four hours post infection, cells were superinfected
with VSV. Susceptibility of BAC36 and BAC-stop45 mutant
infected HFF cells to VSV superinfection were analyzed for
looking for expression levels of VSV-G protein by a Western
blot on cell lysates probed with a rabbit polyclonal anti-VSV-G
antibody.
Supporting Information
Table S1 Comparison of Expression of Human Interferons and
Their Responsive Genes between the Cells Infected with Wild-
type (BAC36) and ORF45-null (BAC-stop45) Mutant KSHV
Revealed by an RT
2 Profiler PCR Array.
Found at: doi:10.1371/journal.pone.0010573.s001 (0.15 MB
DOC)
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